35 related articles for article (PubMed ID: 29544149)
1. Anticancer evaluation and molecular modeling of multi-targeted kinase inhibitors based pyrido[2,3-d]pyrimidine scaffold.
Elzahabi HSA; Nossier ES; Khalifa NM; Alasfoury RA; El-Manawaty MA
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):546-557. PubMed ID: 29482389
[TBL] [Abstract][Full Text] [Related]
2. Structure-Guided Discovery and Preclinical Assessment of Novel (Thiophen-3-yl)aminopyrimidine Derivatives as Potent ERK1/2 Inhibitors.
Shuai W; Xiao H; Yang P; Zhang Y; Bu F; Wu Y; Sun Q; Wang G; Ouyang L
J Med Chem; 2024 Apr; 67(8):6425-6455. PubMed ID: 38613499
[TBL] [Abstract][Full Text] [Related]
3. Discovery of N-(4-((6-(3,5- Dimethoxyphenyl)-9H-purine derivatives as irreversible covalent FGFR inhibitors.
Wang Y; Pan Y; Lv Z; Gou S
Eur J Med Chem; 2024 May; 271():116415. PubMed ID: 38643670
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a highly selective inhibitor of the Aurora kinases.
Ferguson FM; Doctor ZM; Chaikuad A; Sim T; Kim ND; Knapp S; Gray NS
Bioorg Med Chem Lett; 2017 Sep; 27(18):4405-4408. PubMed ID: 28818446
[TBL] [Abstract][Full Text] [Related]
5. Design and Synthesis of DDR1 Inhibitors with a Desired Pharmacophore Using Deep Generative Models.
Yoshimori A; Asawa Y; Kawasaki E; Tasaka T; Matsuda S; Sekikawa T; Tanabe S; Neya M; Natsugari H; Kanai C
ChemMedChem; 2021 Mar; 16(6):955-958. PubMed ID: 33289306
[TBL] [Abstract][Full Text] [Related]
6. PDGFRα/β heterodimer activation negatively affects downstream ERK1/2 signaling and cellular proliferation.
Campaña MB; Perkins MR; McCabe MC; Neumann A; Larson ED; Fantauzzo KA
bioRxiv; 2023 Dec; ():. PubMed ID: 38234806
[TBL] [Abstract][Full Text] [Related]
7. Tumor biomarkers for diagnosis, prognosis and targeted therapy.
Zhou Y; Tao L; Qiu J; Xu J; Yang X; Zhang Y; Tian X; Guan X; Cen X; Zhao Y
Signal Transduct Target Ther; 2024 May; 9(1):132. PubMed ID: 38763973
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and cytotoxic activity evaluation of novel imidazopyridine carbohydrazide derivatives.
Firouzi M; Haghighijoo Z; Eskandari M; Mohabbati M; Miri R; Jamei MH; Poustforoosh A; Nazari S; Firuzi O; Khoshneviszadeh M; Edraki N
BMC Chem; 2024 Jan; 18(1):6. PubMed ID: 38184605
[TBL] [Abstract][Full Text] [Related]
9. Electrochemical [4 + 1] Tandem sp
Wang Q; Yao X; Xu XJ; Zhang S; Ren L
ACS Omega; 2022 Feb; 7(5):4305-4310. PubMed ID: 35155923
[TBL] [Abstract][Full Text] [Related]
10. CBr
Wang Q; Zha M; Zhou F; Chen X; Wang B; Liu G; Qian L
ACS Omega; 2021 Aug; 6(31):20303-20308. PubMed ID: 34395978
[TBL] [Abstract][Full Text] [Related]
11. S100A8 and S100A9 Promote Apoptosis of Chronic Eosinophilic Leukemia Cells.
Lee JS; Lee NR; Kashif A; Yang SJ; Nam AR; Song IC; Gong SJ; Hong MH; Kim G; Seok PR; Lee MS; Sung KH; Kim IS
Front Immunol; 2020; 11():1258. PubMed ID: 32903598
[TBL] [Abstract][Full Text] [Related]
12. Renal Clearable Theranostic Nanoplatforms for Gastrointestinal Stromal Tumors.
Kang H; Stiles WR; Baek Y; Nomura S; Bao K; Hu S; Park GK; Jo MJ; I H; Coll JL; Rubin BP; Choi HS
Adv Mater; 2020 Feb; 32(6):e1905899. PubMed ID: 31854033
[TBL] [Abstract][Full Text] [Related]
13. "Let my liver rather heat with wine" - a review of hepatic fibrosis pathophysiology and emerging therapeutics.
Moscoso CG; Steer CJ
Hepat Med; 2019; 11():109-129. PubMed ID: 31565001
[TBL] [Abstract][Full Text] [Related]
14. Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia.
Wang Q; Liu F; Qi S; Qi Z; Yan XE; Wang B; Wang A; Wang W; Chen C; Liu X; Jiang Z; Hu Z; Wang L; Wang W; Ren T; Zhang S; Yun CH; Liu Q; Liu J
Eur J Med Chem; 2018 Apr; 150():366-384. PubMed ID: 29544149
[TBL] [Abstract][Full Text] [Related]
15. Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC.
Chen Y; Wu J; Wang A; Qi Z; Jiang T; Chen C; Zou F; Hu C; Wang W; Wu H; Hu Z; Wang W; Wang B; Wang L; Ren T; Zhang S; Liu Q; Liu J
Eur J Med Chem; 2017 Oct; 139():674-697. PubMed ID: 28850922
[TBL] [Abstract][Full Text] [Related]
16. Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia.
Liu X; Wang B; Chen C; Jiang Z; Hu C; Wu H; Zhang Y; Liu X; Wang W; Wang J; Hu Z; Wang A; Huang T; Liu Q; Wang W; Wang L; Wang W; Ren T; Li L; Xia R; Ge J; Liu Q; Liu J
Eur J Med Chem; 2018 Dec; 160():61-81. PubMed ID: 30317026
[TBL] [Abstract][Full Text] [Related]
17. Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia.
Liang X; Liu X; Wang B; Zou F; Wang A; Qi S; Chen C; Zhao Z; Wang W; Qi Z; Lv F; Hu Z; Wang L; Zhang S; Liu Q; Liu J
J Med Chem; 2016 Mar; 59(5):1984-2004. PubMed ID: 26789553
[TBL] [Abstract][Full Text] [Related]
18. [Oncogene Fip1-likeL/PDGFRalpha as a target for imatinib in patients with hypereosinophilic syndrome and chronic eosinophilic leukemia. A novel look at pathogenesis and therapy].
Helbig G; Stella-Hołowiecka B; Hołowiecki J
Pol Arch Med Wewn; 2005 May; 113(5):490-7. PubMed ID: 16479834
[No Abstract] [Full Text] [Related]
19. Non-ATP competitive protein kinase inhibitors.
Garuti L; Roberti M; Bottegoni G
Curr Med Chem; 2010; 17(25):2804-21. PubMed ID: 20586715
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]